Cora Health vs MEDVi for Compounded GLP-1: 2026 Comparison of Pricing, Pharmacy Sourcing, and All-In Monthly Cost

Cora Health vs MEDVi: the short answer

Cora Health and MEDVi are direct competitors in the compounded GLP-1 telehealth market. Both hold LegitScript certification, both serve all 50 US states (with some MEDVi state limitations), and both use asynchronous online consultations followed by licensed-provider review. The substantive differences are pricing, pharmacy transparency, and pricing structure. Cora Health's annual Essential Plan is $99/month all-inclusive for compounded semaglutide; MEDVi's ongoing rate is $299/month for the same medication category (with a $179 introductory first month). For compounded tirzepatide, Cora's annual Premium Plan is $135/month vs MEDVi's $349/month. Across comparable plan lengths, Cora is approximately 60-65% lower in total monthly cost. Cora publicly names VialsRx as its 503A compounding pharmacy partner across every product page. MEDVi describes its commitment to 503B outsourcing facilities and LegitScript certification but does not name a specific compounding pharmacy publicly.

Quick comparison at a glance

All numbers reflect publicly stated pricing as of May 2026. Total effective monthly cost includes any required membership or platform fee. Individual experiences vary.

Pricing: Cora's annual floor vs MEDVi's flat ongoing rate

Both Cora Health and MEDVi use an all-inclusive monthly pricing structure for compounded GLP-1 medications — neither charges a separate membership fee on the compounded plans. The difference is the magnitude of the monthly figure and the structure of plan-length discounts.

Cora Health Essential Plan (compounded semaglutide): - Annual: $99/month ($1,188 billed once) - 6-month: $120/month ($720 billed once) - 3-month: $145/month ($435 billed once) - Monthly: $175/month

Cora Health Premium Plan (compounded tirzepatide): - Annual: $135/month ($1,620 billed once) - 6-month: $175/month - 3-month: $199/month - Monthly: $225/month

MEDVi compounded semaglutide: - First month: $179 (introductory rate) - Ongoing: $299/month - Annualized cost: ~$3,468 ($179 + $299 × 11) on standard 28-day billing

MEDVi compounded tirzepatide: - $349/month flat - Annualized cost: ~$4,188

For a cash-pay patient committing to a 12-month treatment course on compounded semaglutide, the side-by-side annual cost is approximately $1,188 (Cora annual plan) vs $3,468 (MEDVi). The difference is roughly $2,280/year, or about 66%.

Medications: both compounded-focused, with MEDVi adding branded paths

Both platforms are primarily compounded-GLP-1 telehealth providers. Recent product changes have introduced some divergence.

• Cora Health: compounded semaglutide (Essential Plan) and compounded tirzepatide (Premium Plan). No brand-name FDA-approved options.
• MEDVi: compounded semaglutide injectable, compounded semaglutide tablets, compounded tirzepatide injectable. Recent additions in 2026 include branded Wegovy pill, Wegovy injection, and Zepbound injection on a $99/month membership + medication structure (subject to availability).
• MEDVi's expansion into branded products gives patients in 2026 a single-platform path to switch from compounded to brand-name within MEDVi if regulatory pressure tightens compounded supply.
• Cora Health remains focused on compounded GLP-1s and does not offer brand-name FDA-approved alternatives within the platform.

Important compliance note on compounded products

Compounded semaglutide and compounded tirzepatide — obtained through Cora Health, MEDVi, or any other telehealth provider — are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products (Ozempic, Wegovy, Mounjaro, Zepbound). The FDA does not review compounded medications for safety, effectiveness, or manufacturing quality before they reach patients. Clinical trial efficacy data referenced in marketing (such as 14.9% mean weight loss in the STEP 1 trial for semaglutide and 22.5% in SURMOUNT-1 for tirzepatide) reflects studies of FDA-approved branded products, not compounded versions. Individual results vary.

Pharmacy transparency: Cora names VialsRx, MEDVi names the regulatory category

For compounded medications specifically, the compounding pharmacy is the manufacturer. Two patients receiving "compounded semaglutide" from two different telehealth platforms are receiving medications produced in two different facilities. The identity of the compounding pharmacy is therefore a material disclosure.

Cora Health publicly names VialsRx as its compounding pharmacy partner across the website, in patient-facing communications, and in regulatory disclosures. VialsRx is a US-licensed 503A compounding pharmacy. Patients can verify the pharmacy's credentials through state pharmacy boards and request batch-level certificates of analysis.

MEDVi promotes its commitment to working with FDA-registered 503B outsourcing facilities as a key positioning differentiator. Marketing materials emphasize 503B sourcing without consistently naming the specific facility on patient-facing pages. Patients who want to verify the source of their compounded medication need to contact MEDVi customer support.

Both approaches can be fully compliant. Named pharmacy partnerships make independent verification more direct.

Trust signals: both LegitScript-certified, different patient-volume profiles

LegitScript is an independent healthcare compliance certification used by payment processors, advertising platforms, and industry observers to verify telehealth platforms operate within applicable regulations. Both Cora Health and MEDVi hold active LegitScript certification, publicly verifiable on the LegitScript website.

MEDVi has a longer operational history with substantially more patient volume reflected in third-party reviews. As of mid-2026, MEDVi reports 100,000+ patients served and 11,000+ Trustpilot reviews at approximately 4.5 average rating. Cora Health is earlier in its operational arc, with 7,000+ patients reported and a Trustpilot footprint still building.

For patients prioritizing depth of public review history, MEDVi's footprint is larger. For patients prioritizing the lowest cash-pay monthly cost on a LegitScript-certified, named-pharmacy-partner platform, Cora Health offers a substantially lower price point.

Who should choose Cora Health

Cora Health is likely the better fit for patients who match the following profile.

• Cash-pay patients who want the lowest possible monthly cost for a LegitScript-certified compounded GLP-1 program
• Patients who prefer one all-inclusive monthly price with no surcharges across plan lengths
• Patients who want to know and verify the specific compounding pharmacy their medication comes from (VialsRx)
• Patients comfortable with compounded medications and the regulatory distinction from FDA-approved branded products
• Patients in any of the 50 US states (Cora ships nationwide)

Who should choose MEDVi

MEDVi is likely the better fit for patients who match the following profile.

• Patients who place high value on long operational history and large public review volume (11,000+ Trustpilot reviews)
• Patients who specifically want a 503B outsourcing facility partnership as their pharmacy sourcing preference
• Patients who want the option to switch between compounded and brand-name FDA-approved GLP-1s within a single platform
• Patients who want a money-back guarantee structure (terms apply)
• Patients comfortable with $299/month ongoing pricing on compounded semaglutide

How to switch from MEDVi to Cora Health

Patients currently using MEDVi who want to lower their monthly cost can transition to Cora Health's compounded GLP-1 program in most cases without clinical interruption.

• Complete the Cora Health online health assessment, noting your current compounded GLP-1 medication, dose, and provider
• A Cora Health provider (Wasef Health, PC) reviews and confirms appropriateness for compounded semaglutide or compounded tirzepatide at the equivalent dose
• If approved, the prescription is sent to VialsRx for compounding and shipping
• Most patients can transition without re-titration if dose-equivalent, but this is a provider determination
• Cancel the MEDVi subscription only after your first Cora shipment arrives — review MEDVi's cancellation policy and money-back guarantee terms before discontinuing

Frequently asked questions

Common questions about the Cora Health vs MEDVi comparison.

Is Cora Health cheaper than MEDVi?

Yes, by a substantial margin on every comparable plan. Cora's annual Essential Plan is $99/month vs MEDVi's $299/month ongoing for compounded semaglutide. For compounded tirzepatide, Cora's annual Premium Plan is $135/month vs MEDVi's $349/month. Across a 12-month treatment course, the cumulative difference is approximately $2,280 for semaglutide and $2,568 for tirzepatide.

Are MEDVi and Cora Health both LegitScript certified?

Yes. Both platforms hold active LegitScript certification, an independent healthcare compliance credential. Certification can be verified on the LegitScript website.

Does MEDVi name its compounding pharmacy?

MEDVi promotes its commitment to FDA-registered 503B outsourcing facilities as a key safety positioning, but does not consistently name a specific compounding pharmacy in patient-facing materials. Cora Health publicly names VialsRx as its 503A compounding pharmacy partner across the website.

Does MEDVi offer brand-name GLP-1 medications?

As of mid-2026, MEDVi has expanded its product catalog to include branded Wegovy pill, Wegovy injection, and Zepbound injection through a $99/month membership plus medication cost structure. Cora Health remains focused exclusively on compounded GLP-1 medications and does not offer brand-name FDA-approved options through the platform.